TABLE 3.
Antibiotic treatment outcomes and related adverse events for 190 patients with health care-associated MRSA bacteremiaa
| Variable | Treatment group |
Treatment outcome |
|||||
|---|---|---|---|---|---|---|---|
| All (n = 190) | Vancomycin (n = 134) | Teicoplanin (n = 56) | P | Success (n = 112, 58.9%) | Failure (n = 78, 41.1%) | P | |
| Antibiotic treatment | |||||||
| No. (%) with interval from culture to VAN or TEC treatment of ≥48 h | 64 (41.8) | 42 (39.3) | 22 (47.8) | 0.324 | 38 (40.9) | 26 (43.3) | 0.762 |
| Duration of VAN or TEC treatment (days), median (IQR) | 14 (3–23) | 14 (9–23) | 13 (8–21) | 0.239 | 14 (9–21) | 13 (8–24) | 0.995 |
| Clinical response | |||||||
| Duration of bacteremia after VAN or TEC treatment (days), median (IQR) | 1 (0–2) | 1 (0–2) | 0 (0–1) | 0.254 | 0 (1–0) | 1 (0–7) | <0.001 |
| No. (%) with bacteremia ≥7 days after VAN or TEC treatment | 20 (10.9) | 15 (11.7) | 5 (9.1) | 0.601 | 0 | 20 (25.6) | <0.001 |
| Duration of fever after VAN or TEC treatment (days), median (IQR) | 4 (2–7) | 4 (2–6) | 5 (2–11) | 0.084 | 3 (2–5) | 8 (4–17) | <0.001 |
| No. (%) with fever ≥7 days after VAN or TEC treatment | 51 (29.5) | 29 (24.0) | 22 (42.3) | 0.015 | 0 | 51 (67.1) | <0.001 |
| No. (%) with drug-related adverse events during treatment) | 36 (18.9) | 28 (20.9) | 8 (14.3) | 0.289 | 19 (17.0) | 17 (21.8) | 0.403 |
| No. (%) with acute renal injury | 17 (8.9) | 14 (10.4) | 3 (5.4) | 0.262 | 6 (5.4) | 11 (14.1) | 0.038 |
| No. (%) with hepatotoxicity | 3 (1.6) | 1 (0.7) | 2 (3.6) | 0.208 | 3 (2.7) | 0 | 0.270 |
| No. (%) with bone marrow toxicity | 10 (5.3) | 8 (6.0) | 2 (3.6) | 0.726 | 8 (7.1) | 2 (2.6) | 0.202 |
| No. (%) with fever | 8 (4.2) | 6 (4.5) | 2 (3.6) | 1.000 | 5 (4.5) | 3 (3.8) | 1.000 |
| No. (%) with rash | 1 (0.5) | 1 (0.7) | 0 | 1.000 | 0 | 1 (1.3) | 0.411 |
| No. (%) with change of initial antibiotics | 36 (18.9) | 20 (14.9) | 16 (28.6) | 0.029 | 17 (15.2) | 19 (24.4) | 0.112 |
| Outcome | |||||||
| No. of days of hospital stay after bacteremia, median (IQR) | 23 (11–49) | 23 (12–49) | 25 (9–52) | 0.706 | 23 (10–47) | 24 (12–53) | 0.867 |
| No. (%) with in-hospital mortality | 66 (34.7) | 45 (33.6) | 21 (37.5) | 0.605 | 27 (24.1) | 39 (50.0) | <0.001 |
| No. (%) with mortality attributable to MRSA | 28 (14.7) | 18 (13.4) | 10 (17.4) | 0.433 | 0 | 28 (35.9) | <0.001 |
a
IQR, interquartile range; VAN, vancomycin; TEC, teicoplanin; MRSA, methicillin-resistant Staphylococcus aureus.